Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.

Sandborn WJ, Chen J, Kisfalvi K, Loftus EV Jr, D'Haens G, Candela N, Lasch K, Wolf DC, Uddin SM, Danese S

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.

Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG

Change in Urgency Status Among Ulcerative Colitis Patients: Understanding a Potential Unmet Patient Need From the CorEvitas Inflammatory Bowel Disease Registry.

Wolf DC, Naegeli AN, Moore PC, Janak JC, Crabtree MM, Shan M, Hunter TM, Sontag A, Cross RK

Is the 90-day dog study necessary for pesticide toxicity testing?

Bishop PL, Dellarco VL, Wolf DC

Towards achieving a modern science-based paradigm for agrochemical carcinogenicity assessment.

Hilton GM, Corvi R, Luijten M, Mehta J, Wolf DC

Challenges and opportunities for overcoming dog use in agrochemical evaluation and registration.

Bishop PL, Brescia S, Brunner R, Casey W, Conlee-Griffin K, Currie RA, Domoradzki J, Embry M, Harris MI, Hartung T, Hilton GM, Hooberman B, Ingle B, Jang KJ, Kinter L, Krall C, Leedale J, Lowit A, Mehta J, Mendez E, Mingoia B, Munarriz E, Murphy L, Myer A, Ottoni A, Panzarea M, Perron M, Pina J, Ramsingh D, Sewell F, Swanson J, Tan YM, Terron A, Trainer MA, Valadares MC, Webb S, Webb E, Willett C, Wolf DC

Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial.

Zisman-Ilani Y, Thompson KD, Siegel LS, Mackenzie T, Crate DJ, Korzenik JR, Melmed GY, Kozuch P, Sands BE, Rubin DT, Regueiro MD, Cross R, Wolf DC, Hanson JS, Schwartz RM, Vrabie R, Kreines MD, Scherer T, Dubinsky MC, Siegel CA

Transforming the evaluation of agrochemicals.

Wolf DC, Bhuller Y, Cope R, Corvaro M, Currie RA, Doe J, Doi A, Hilton G, Mehta J, Saltmiras D, Sewell F, Trainer M, DĂŠglin SE

Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program.

Feagan BG, Schreiber S, Afzali A, Rieder F, Hyams J, Kollengode K, Pearlman J, Son V, Marta C, Wolf DC, D'Haens GG

A new approach to the classification of carcinogenicity.

Doe JE, Boobis AR, Cohen SM, Dellarco VL, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC

Improving Liver Transplant Outcomes for Hepatitis C Virus Hepatocellular Carcinoma in the Direct-Acting Antiviral Therapy Era.

Okumura K, Sogawa H, Samson D, Butler J, Veillette G, John D, Diflo T, Bodin R, Wolf DC, Latifi R, Nishida S

Trends and outcomes of liver transplantation among older recipients in the United States.

Okumura K, Lee JS, Dhand A, Sogawa H, Veillette G, John D, Misawa R, Bodin R, Wolf DC, Diflo T, Nishida S

Fatal acute respiratory distress syndrome caused by blastomycosis after recent orthotopic liver transplantation in a non-endemic area.

Sogawa H, Misawa R, Bodin R, Wolf DC, Nog R, Kleinman G, Nishida S, Epelbaum O

Inferior Liver Transplant Outcomes during early COVID-19 pandemic in United States.

Okumura K, Nishida S, Sogawa H, Veillette G, Bodin R, Wolf DC, Dhand A

Rethinking chronic toxicity and carcinogenicity assessment for agrochemicals project (ReCAAP): A reporting framework to support a weight of evidence safety assessment without long-term rodent bioassays.

Hilton GM, Adcock C, Akerman G, Baldassari J, Battalora M, Casey W, Clippinger AJ, Cope R, Goetz A, Hayes AW, Papineni S, Peffer RC, Ramsingh D, Williamson Riffle B, Sanches da Rocha M, Ryan N, Scollon E, Visconti N, Wolf DC, Yan Z, Lowit A